A Phase I, Single-centre, Randomised, Single-blinded, Placebo-controlled Single Ascending Dose Study, Followed by an Open-label Extension, Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of ALX-0651, Administered Intravenously to Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2012
At a glance
- Drugs ALX 0651 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 16 Apr 2012 Actual patient number (52) added as reported by ClinicalTrials.gov.
- 16 Apr 2012 Planned end date changed from 1 Jun 2012 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 16 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.